Publications by authors named "Martin Reck"

100Publications

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

Lung Cancer 2020 Jun 20;144:76-84. Epub 2020 Apr 20.

Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany; Institute of Pharmacology, Johannes Gutenberg-University Mainz, 55122 Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.04.009DOI Listing
June 2020

Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.

J Thorac Oncol 2020 Aug 27;15(8):1306-1316. Epub 2020 Apr 27.

Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.04.013DOI Listing
August 2020

Challenges in lung cancer therapy during the COVID-19 pandemic.

Lancet Respir Med 2020 06 9;8(6):542-544. Epub 2020 Apr 9.

Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100 Siena, Italy; NIBIT Foundation Onlus, Siena, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(20)30170-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146673PMC
June 2020

Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?

J Thorac Oncol 2020 02;15(2):166-169

LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.12.106DOI Listing
February 2020

Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?

J Thorac Oncol 2020 03;15(3):308-310

LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.11.031DOI Listing
March 2020

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in -rearranged lung cancer.

Cold Spring Harb Mol Case Stud 2019 12 13;5(6). Epub 2019 Dec 13.

Division of Cancer Genome Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a004630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913150PMC
December 2019

Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?

Drugs 2019 Dec;79(18):1937-1945

Department of Oncology, LungenClinic Grosshansdorf, Woehrendamm 80, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-019-01222-wDOI Listing
December 2019

Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy.

Clin Epigenetics 2019 11 12;11(1):157. Epub 2019 Nov 12.

Pathology of the University Medical Center Schleswig-Holstein, Campus Lübeck and the Research Center Borstel, Leibniz Lung Center, Borstel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-019-0770-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852724PMC
November 2019

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.

Eur J Cancer 2019 11 28;122:109-114. Epub 2019 Oct 28.

Department of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.09.012DOI Listing
November 2019

Perceived relatedness, death acceptance, and demoralization in patients with cancer.

Support Care Cancer 2020 Jun 30;28(6):2693-2700. Epub 2019 Oct 30.

Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52 - W26, 20246, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-05088-2DOI Listing
June 2020

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2019 11 28;381(21):2020-2031. Epub 2019 Sep 28.

From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology-Germans Trias i Pujol Hospital, Badalona (E.C.C.) - all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K.) and the Samsung Medical Center at Sungkyunkwan University School of Medicine (K.P.) - both in Seoul, South Korea; the Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania (A.A.); the Hospital Italiano de Buenos Aires, Buenos Aires (L.L.); Instituto Jalisciense de Cancerologia, Guadalajara, Mexico (E.M.J.); the Saitama Cancer Center, Saitama, Japan (H.S.); Matrai Gyogyintezet, Matrahaza, Hungary (I.A.); Limoges University Hospital, Limoges (A.V.), and Aix-Marseille University, National Center for Scientific Research, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - all in France; Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland (S.P.); Sotiria General Hospital, National and Kapodistrian University of Athens, Athens (K.S.); Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.); Fox Chase Cancer Center, Philadelphia (H.B.); Johns Hopkins Kimmel Cancer Center, Baltimore (J.R.B.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., P.B., S.K.R., R.S.K., F.E.N.); and Winship Cancer Institute, Emory University, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910231DOI Listing
November 2019

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers.

J Oncol 2019 22;2019:8970645. Epub 2019 Aug 22.

Department of Oncology, Hematology and Bone Marrow Tansplantation with Section Pneumology, Hubertus University Medical Center Hamburg-Eppendorf, Hubertus Wald Tumorzentrum (University Cancer Center Hamburg), University Medical Center Hamburg, 25 Martinistrasse Str., Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8970645DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724438PMC
August 2019

Immune checkpoint blockade in small cell lung cancer.

Lung Cancer 2019 11 22;137:31-37. Epub 2019 Aug 22.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.08.024DOI Listing
November 2019

Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.

Lung Cancer 2019 10 13;136:145-147. Epub 2019 Aug 13.

The University of Manchester, Division of Cancer Sciences, The Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.08.007DOI Listing
October 2019

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

Lung Cancer 2019 08 19;134:245-253. Epub 2019 Jun 19.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.06.007DOI Listing
August 2019

Nivolumab plus ipilimumab in non-small-cell lung cancer.

Future Oncol 2019 Jul 8;15(19):2287-2302. Epub 2019 May 8.

Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, QLD 4102, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0031DOI Listing
July 2019

Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.

Clin Cancer Res 2019 08 25;25(16):4881-4887. Epub 2019 Mar 25.

Airway Research Center North in the German Center for Lung Research (DZL), Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1894DOI Listing
August 2019

Characterizing death acceptance among patients with cancer.

Psychooncology 2019 04 10;28(4):854-862. Epub 2019 Mar 10.

Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.5030DOI Listing
April 2019

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncol 2019 Apr 13;15(12):1363-1383. Epub 2019 Feb 13.

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany & Institute of Pharmacology, Johannes Gutenberg-University Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0948DOI Listing
April 2019

Prospects of targeted and immune therapies in SCLC.

Expert Rev Anticancer Ther 2019 02 28;19(2):151-167. Epub 2018 Dec 28.

d Airway Research Center North (ARCN), German Center for Lung Research , LungenClinic , Grosshansdorf , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1559057DOI Listing
February 2019

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

N Engl J Med 2018 12 25;379(24):2342-2350. Epub 2018 Sep 25.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), Florida Cancer Specialists, Fleming Island (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga (D.D.), and Sarah Cannon Research Institute, Nashville (D.D., D.R.S.) - both in Tennessee; Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.K.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Adelaide, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukoelln, Berlin (M.W.), and the Lung Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.) - both in Germany; Centre Hospitalier Universitaire de Liège, Liège (M.B.), and University Hospitals KU Leuven, Leuven (J.V.) - both in Belgium; Centre Hospitalier Universitaire de Montpellier and Institut du Cancer de Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); the University of Manchester and the Christie NHS Foundation Trust, Manchester (C.F.-F.), AstraZeneca, Alderley Park (C.W.), and AstraZeneca, Cambridge (M.T.) - all in the United Kingdom; AstraZeneca, Gaithersburg, MD (G.M., P.A.D.); and Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1809697DOI Listing
December 2018

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

Atezolizumab Treatment of Nonsquamous NSCLC.

N Engl J Med 2018 09;379(12):1188

Florida Hospital Cancer Institute, Orlando, FL

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1809195
Publisher Site
http://dx.doi.org/10.1056/NEJMc1809195DOI Listing
September 2018

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

J Thorac Oncol 2018 12 8;13(12):e243-e246. Epub 2018 Sep 8.

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183304
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.08.2025DOI Listing
December 2018

Patient-reported outcomes with nivolumab in advanced solid cancers.

Cancer Treat Rev 2018 Nov 2;70:75-87. Epub 2018 Aug 2.

Bristol-Myers Squibb, Rt 206 & Province Line Road, Princeton, NJ 08543, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.08.001DOI Listing
November 2018

Crizotinib.

Recent Results Cancer Res 2018;211:57-65

Department of Thoracic Oncology, LungenClinic Grosshansdorf, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-91442-8_4DOI Listing
November 2018

Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same….

J Thorac Oncol 2018 08 2;13(8):1060-1061. Epub 2018 Jul 2.

Thoracic Oncology, LungenClinic Großhansdorf, Großhansdorf, Germany; Airway Research Center North, German Center for Lung Research (DZL), Großhansdorf, Germany; University of Lübeck, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.001DOI Listing
August 2018

Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis.

Respir Res 2018 07 24;19(1):138. Epub 2018 Jul 24.

Pathology of the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck and the Research Center Borstel, Parkallee 3a, 23845, Borstel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12931-018-0841-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056940PMC
July 2018

Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.

J Thorac Dis 2018 May;10(Suppl 13):S1468-S1473

Lungenclinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.01.112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994502PMC
May 2018

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

N Engl J Med 2018 Jun 4;378(24):2288-2301. Epub 2018 Jun 4.

From the Florida Hospital Cancer Institute, Orlando (M.A.S.); Rocky Mountain Cancer Centers, Denver (R.M.J.); US Oncology, Houston (R.M.J.); Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy (F.C.); Instituto Nacional del Torax, Santiago, Chile (F.O.); Moscow City Oncology Hospital, Moscow (D.S.); National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan (N.N.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain (D.R.-A.); Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble (D.M.-S.), and Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - both in France; New England Cancer Specialists, Scarborough, ME (C.A.T.); Allegheny Health Network Cancer Institute, Pittsburgh (G.F.); Genentech, South San Francisco, CA (C.K., A.L., S.C., Y.D., Y.S., M.K., A.L.-C., A.S.); and Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716948
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716948DOI Listing
June 2018

Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 06 30;36(17):1647-1648. Epub 2018 Apr 30.

Niels Reinmuth, Asklepios Clinics Munich-Gauting, Gauting, Germany; and Martin Reck, German Center for Lung Research, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2102DOI Listing
June 2018

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

N Engl J Med 2018 May 16;378(22):2078-2092. Epub 2018 Apr 16.

From NYU Perlmutter Cancer Center, New York (L.G.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria (D.R.-A.), Hospital Universitario Central de Asturias, Oviedo (E.E.), Vall d'Hebron University, Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Fundación Jiménez Díaz (M.D.) and Hospital Universitario Quirón Madrid (B.R.-V.), Madrid - all in Spain; Karmanos Cancer Institute, Detroit (S.G.); Integrated Health and Social Services Centres, Montérégie Centre, Greenfield Park, QC (F.D.A.), and Sunnybrook Health Sciences Centre, Toronto (S.Y.-S.C.) - both in Canada; Southern Medical Day Care Centre, Wollongong, NSW (P.C.), Epworth Healthcare, Richmond, VIC (R.R.J.), Westmead Hospital and University of Sydney, Sydney (R.H.), and Chris O'Brien Lifehouse, Camperdown, NSW (M.B.) - all in Australia; Otto Wagner Hospital, Vienna (M.J.H.); Sanford Health, Sioux Falls, SD (S.F.P.); Thoraxklinik, Heidelberg (H.G.B.), and LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.) - both in Germany; Davidoff Cancer Center, Tel Aviv University, Petah Tikva, Israel (N.P.); Ospedale Policlinico San Martino, Genoa (F.G.), University of Turin, Azienda Ospedaliero-Universitaria San Luigi, Orbassano (S.N.), and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.C.G.) - all in Italy; David Geffen School of Medicine at UCLA, Los Angeles (E.B.G.); Kansai Medical University Hospital, Osaka, Japan (T.K.); Moffitt Cancer Center, Tampa, FL (J.E.G.); and Merck, Kenilworth, NJ (J.V., Z.W., J.Y., H.R., M.C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1801005DOI Listing
May 2018

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 May 16;378(22):2093-2104. Epub 2018 Apr 16.

From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia, Italy (E.M.); First Department of Oncology, Metropolitan Hospital, Athens, Greece (H.L.); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (S.B.); Fundación Arturo López Pérez, Santiago, Chile (P.S.); Fox Chase Cancer Center, Philadelphia (H.B.); Winship Cancer Institute, Emory University, Atlanta (S.S.R.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.B.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., G.G., H.C., J.S., P.B., D.H., Y.F., F.N.); and Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and CiberOnc, Madrid (L.P.-A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1801946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193684PMC
May 2018

[CT-Screening for Lung Cancer - what is the Evidence?]

Dtsch Med Wochenschr 2018 Apr 3;143(7):494-497. Epub 2018 Apr 3.

Onkologischer Schwerpunkt, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0043-104919DOI Listing
April 2018

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

J Clin Oncol 2018 03 5;36(9):911-919. Epub 2018 Feb 5.

Gregory P. Kalemkerian and Madelyn Lew, University of Michigan, Ann Arbor; James Pantelas, Greater Detroit Area; Michael Simoff, Henry Ford Hospital, Detroit, MI; Navneet Narula, Weill Cornell Medical College; Jessica Donington, New York University School of Medicine: Anjali Saqi, Columbia University Medical Center, New York, NY; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; William A. Biermann, Chestnut Hill Hospital and Mercy Suburban Hospital, East Norriton; Baskaran Sundaram, Thomas Jefferson Medical School, Philadelphia, PA; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, ON, Canada; Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA; Martin Reck, Lung Clinic Grosshansdorf, Grosshansdorf, Germany; and Navneet Singh, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.7293
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.7293DOI Listing
March 2018

Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression.

Clin Epigenetics 2017 28;9:123. Epub 2017 Nov 28.

Pathology of the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck and the Research Center Borstel Parkallee 3, 23845 Borstel, Germany.

View Article

Download full-text PDF

Source
https://clinicalepigeneticsjournal.biomedcentral.com/article
Publisher Site
http://dx.doi.org/10.1186/s13148-017-0423-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704452PMC
July 2018

Lung cancer in 2017: Giant steps and stumbling blocks.

Nat Rev Clin Oncol 2018 02 21;15(2):71-72. Epub 2017 Nov 21.

Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Centre North (ARCN), German Center for Lung Research (DZL), Woehrendamm 80, Grosshansdorf, Schleswig-Holstein 22927, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.178DOI Listing
February 2018

Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.

Authors:
Martin Reck

Immunotherapy 2018 02 17;10(2):93-105. Epub 2017 Nov 17.

Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0121DOI Listing
February 2018

Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2017 11;377(20):1999

LungenClinic Grosshansdorf, Grosshansdorf, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1712794DOI Listing
November 2017

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.

Lung Cancer 2017 11 1;113:37-44. Epub 2017 Sep 1.

Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Centre for Lung Research (DZL), Wöhrendamm 80, Grosshansdorf, 22927, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.021DOI Listing
November 2017

Response to Letter to the Editor.

J Thorac Oncol 2017 11;12(11):e192

Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.08.018DOI Listing
November 2017

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.9012DOI Listing
November 2017

Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2017 Aug;377(9):849-861

From LungenClinic Grosshansdorf and Airway Research Center North, Grosshansdorf (M.R., K.F.R.), the German Center for Lung Research, Giessen (M.R., K.F.R.), University of Lübeck, Lübeck (M.R.), and Christian Albrechts University Kiel, Kiel (K.F.R.) - all in Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1703413DOI Listing
August 2017

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Oct 30;35(30):3449-3457. Epub 2017 Aug 30.

Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University, Seoul; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju-si, Republic of Korea; Claus-Peter Schneider, Zentralklinik Bad Berka, Bad Berka; Joachim Von Pawel, Asklepius Fachkliniken, Gauting; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Pablo Fernando Gonzalez Mella, Centro de Investigaciones Clinicas, Universidad de Valparaíso and Fundación Arturo López Pérez, Santiago, Chile; Fabrice Barlesi, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Baohui Han, Shanghai Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai; Li Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China; Doina Elena Ganea, Spitalul Judetean De Urgenta Suceava, Sfântul loan cel Nou, Suceava, Romania; Vladimir Vladimirov, State Healthcare Institute, Pyatigorsk Oncology Dispensary, Pyatigorsk; Natalia Fadeeva, Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Tomohide Tamura, St Luke's International Hospital, Tokyo, Japan; Pieter E. Postmus, University of Liverpool, Liverpool, United Kingdom; Kenneth O'Byrne, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia; and Justin Kopit, Mingshun Li, and Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.7629
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.7629DOI Listing
October 2017

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.

Target Oncol 2017 08;12(4):475-485

Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), 22927, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0517-2DOI Listing
August 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017